NEI
NBIX icon

Northwest & Ethical Investments’s Neurocrine Biosciences NBIX Stock Holding History

Northwest & Ethical Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-600
Closed -$73.8K – 396
2018
Q3 		$73.8K Sell
600
-600
-50% -$68.1K ﹤0.01% 344
2018
Q2 		$118K Buy
1,200
+100
+9% +$8.95K 0.01% 346
2018
Q1 		$91.2K Buy
+1,100
New +$92.9K 0.01% 344

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Northwest & Ethical Investments's NBIX Position: Q4 2018 in Review

Northwest & Ethical Investments sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 600 shares — an estimated $73.8K sold.

Northwest & Ethical Investments first reported a position in NBIX in Q1 2018 and held it in 3 quarters. The position peaked at $118K in Q2 2018. 330 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

  • Northwest & Ethical Investments reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
  • Northwest & Ethical Investments sold 600 Neurocrine Biosciences shares in Q4 2018, an estimated $73.8K.
  • Northwest & Ethical Investments first reported a position in Neurocrine Biosciences in Q1 2018 and held it in 3 quarters.
  • Northwest & Ethical Investments's Neurocrine Biosciences position peaked at $118K in Q2 2018.
  • 330 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on Northwest & Ethical Investments's 13F filing for Q4 2018, filed 8 Jul 2025.